Sino Biopharmaceutical Limited (1177.HK)
HKD 3.97
(1.53%)
HKD 3.97
(1.53%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 2.33 Billion CNY | -53.39% |
| 2022 | 5 Billion CNY | -65.76% |
| 2021 | 14.6 Billion CNY | 236.55% |
| 2020 | 4.34 Billion CNY | -7.53% |
| 2019 | 4.69 Billion CNY | -48.11% |
| 2018 | 9.04 Billion CNY | 316.7% |
| 2017 | 2.17 Billion CNY | 26.72% |
| 2016 | 1.71 Billion CNY | 15.02% |
| 2015 | 1.48 Billion CNY | 23.09% |
| 2014 | 1.21 Billion CNY | 49.36% |
| 2013 | 810.13 Million CNY | 12.95% |
| 2012 | 717.23 Million CNY | 91.49% |
| 2011 | 374.55 Million CNY | -22.47% |
| 2010 | 483.12 Million CNY | 38.23% |
| 2009 | 349.5 Million CNY | 33.37% |
| 2008 | 262.05 Million CNY | 24.68% |
| 2007 | 210.17 Million CNY | 48.48% |
| 2006 | 141.55 Million CNY | -91.77% |
| 2005 | 1.72 Billion CNY | 859.18% |
| 2004 | 179.34 Million CNY | 106.1% |
| 2003 | 87.01 Million CNY | 42.93% |
| 2002 | 60.88 Million CNY | -7.07% |
| 2001 | 65.51 Million CNY | 35.77% |
| 2000 | 48.25 Million CNY | 26.5% |
| 1999 | 38.14 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 1.5 Billion CNY | 0.0% |
| 2024 Q2 | 1.5 Billion CNY | 0.0% |
| 2023 Q2 | 629.39 Million CNY | 0.0% |
| 2023 Q1 | 629.39 Million CNY | 463.39% |
| 2023 Q3 | - HKD | -100.0% |
| 2023 FY | 2.33 Billion CNY | -53.39% |
| 2022 Q3 | 311.26 Million CNY | -67.59% |
| 2022 Q2 | 960.51 Million CNY | 0.0% |
| 2022 Q1 | 960.51 Million CNY | -68.65% |
| 2022 FY | 5 Billion CNY | -65.76% |
| 2022 Q4 | -173.19 Million CNY | -155.64% |
| 2021 Q2 | 6.56 Billion CNY | 243.19% |
| 2021 Q3 | 3.06 Billion CNY | -53.34% |
| 2021 Q4 | 3.06 Billion CNY | 0.0% |
| 2021 FY | 14.6 Billion CNY | 236.55% |
| 2021 Q1 | 1.91 Billion CNY | 38.85% |
| 2020 Q4 | 1.37 Billion CNY | 45.64% |
| 2020 Q2 | 963.66 Million CNY | 11.79% |
| 2020 FY | 4.34 Billion CNY | -7.53% |
| 2020 Q1 | 862.02 Million CNY | -17.25% |
| 2020 Q3 | 946.23 Million CNY | -1.81% |
| 2019 Q4 | 1.04 Billion CNY | 28.42% |
| 2019 FY | 4.69 Billion CNY | -48.11% |
| 2019 Q1 | 856.7 Million CNY | -87.48% |
| 2019 Q3 | 811.16 Million CNY | 38.04% |
| 2019 Q2 | 587.64 Million CNY | -31.41% |
| 2018 Q4 | 6.84 Billion CNY | 719.19% |
| 2018 FY | 9.04 Billion CNY | 316.7% |
| 2018 Q1 | 771.1 Million CNY | 110.69% |
| 2018 Q2 | 594.56 Million CNY | -22.89% |
| 2018 Q3 | 835.58 Million CNY | 40.54% |
| 2017 Q4 | 365.99 Million CNY | -48.04% |
| 2017 Q3 | 704.37 Million CNY | 35.05% |
| 2017 Q2 | 521.57 Million CNY | -9.92% |
| 2017 FY | 2.17 Billion CNY | 26.72% |
| 2017 Q1 | 579.01 Million CNY | 55.26% |
| 2016 Q4 | 372.92 Million CNY | -21.85% |
| 2016 Q1 | 440.26 Million CNY | 26.57% |
| 2016 FY | 1.71 Billion CNY | 15.02% |
| 2016 Q2 | 422.77 Million CNY | -3.97% |
| 2016 Q3 | 477.18 Million CNY | 12.87% |
| 2015 Q4 | 347.85 Million CNY | -12.59% |
| 2015 Q1 | 320.22 Million CNY | 9.15% |
| 2015 Q3 | 397.95 Million CNY | -6.01% |
| 2015 FY | 1.48 Billion CNY | 23.09% |
| 2015 Q2 | 423.4 Million CNY | 32.22% |
| 2014 Q1 | 267.05 Million CNY | 79.24% |
| 2014 Q4 | 293.37 Million CNY | -28.29% |
| 2014 Q3 | 409.09 Million CNY | 70.1% |
| 2014 Q2 | 240.5 Million CNY | -9.94% |
| 2014 FY | 1.21 Billion CNY | 49.36% |
| 2013 Q4 | 148.99 Million CNY | -46.13% |
| 2013 FY | 810.13 Million CNY | 12.95% |
| 2013 Q1 | 212 Million CNY | 1.44% |
| 2013 Q2 | 172.55 Million CNY | -18.61% |
| 2013 Q3 | 276.57 Million CNY | 60.28% |
| 2012 FY | 717.23 Million CNY | 91.49% |
| 2012 Q4 | 208.98 Million CNY | -7.11% |
| 2012 Q3 | 224.97 Million CNY | 91.4% |
| 2012 Q1 | 165.72 Million CNY | 16.45% |
| 2012 Q2 | 117.53 Million CNY | -29.08% |
| 2011 Q1 | 87.14 Million CNY | 0.0% |
| 2011 Q2 | 96.74 Million CNY | 11.02% |
| 2011 Q3 | 48.35 Million CNY | -50.02% |
| 2011 Q4 | 142.31 Million CNY | 194.32% |
| 2011 FY | 374.55 Million CNY | -22.47% |
| 2010 Q1 | 79.37 Million CNY | 0.0% |
| 2010 Q2 | 88.85 Million CNY | 11.94% |
| 2010 FY | 483.12 Million CNY | 38.23% |
| 2009 FY | 349.5 Million CNY | 33.37% |
| 2008 FY | 262.05 Million CNY | 24.68% |
| 2007 FY | 210.17 Million CNY | 48.48% |
| 2006 FY | 141.55 Million CNY | -91.77% |
| 2005 FY | 1.72 Billion CNY | 859.18% |
| 2004 FY | 179.34 Million CNY | 106.1% |
| 2003 FY | 87.01 Million CNY | 42.93% |
| 2002 FY | 60.88 Million CNY | -7.07% |
| 2001 FY | 65.51 Million CNY | 35.77% |
| 2000 FY | 48.25 Million CNY | 26.5% |
| 1999 FY | 38.14 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 70.87 Million HKD | -3190.167% |
| CK Life Sciences Int'l., (Holdings) Inc. | 17.25 Million HKD | -13418.487% |